CN114555088A - 包含赛乐西帕的药物组合物 - Google Patents

包含赛乐西帕的药物组合物 Download PDF

Info

Publication number
CN114555088A
CN114555088A CN202080071283.2A CN202080071283A CN114555088A CN 114555088 A CN114555088 A CN 114555088A CN 202080071283 A CN202080071283 A CN 202080071283A CN 114555088 A CN114555088 A CN 114555088A
Authority
CN
China
Prior art keywords
pharmaceutical composition
amount
disease
pulmonary hypertension
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080071283.2A
Other languages
English (en)
Chinese (zh)
Inventor
马克·帕特里克·施拉德尔
亚历山德拉·施利克尔-斯佩因
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN114555088A publication Critical patent/CN114555088A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080071283.2A 2019-10-23 2020-10-22 包含赛乐西帕的药物组合物 Pending CN114555088A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2019/078905 2019-10-23
EP2019078905 2019-10-23
PCT/EP2020/079698 WO2021078835A1 (en) 2019-10-23 2020-10-22 Pharmaceutical composition comprising selexipag

Publications (1)

Publication Number Publication Date
CN114555088A true CN114555088A (zh) 2022-05-27

Family

ID=75620412

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080071283.2A Pending CN114555088A (zh) 2019-10-23 2020-10-22 包含赛乐西帕的药物组合物

Country Status (15)

Country Link
US (1) US20220401441A1 (https=)
EP (1) EP4048235A1 (https=)
JP (2) JP7646646B2 (https=)
KR (1) KR20220087443A (https=)
CN (1) CN114555088A (https=)
AU (1) AU2020369912A1 (https=)
BR (1) BR112022007207A2 (https=)
CA (1) CA3154802A1 (https=)
EC (1) ECSP22040921A (https=)
IL (1) IL292354A (https=)
JO (1) JOP20220093A1 (https=)
MX (1) MX2022004882A (https=)
PE (1) PE20221455A1 (https=)
PH (1) PH12022550937A1 (https=)
WO (1) WO2021078835A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116392491A (zh) * 2023-04-11 2023-07-07 广东省实验动物监测所 司来帕格的药物组合物及其制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR2022005274A1 (tr) * 2022-04-05 2023-10-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Seleksi̇pag'in bi̇r kati di̇spersi̇yonunu i̇çeren bi̇r fi̇lm kapli tablet
TR2022005277A2 (tr) * 2022-04-05 2023-10-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Yaş granülasyon i̇le i̇şlenmi̇ş seleksi̇pag i̇çeren bi̇r fi̇lm kapli tablet
TR2022005273A2 (tr) * 2022-04-05 2023-10-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Seleksi̇pag i̇çeren bi̇r fi̇lm kapli tablet
TR2022020995A1 (tr) * 2022-12-28 2024-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Seleksi̇pag i̇çeren bi̇r tablet formülasyonu

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108289890A (zh) * 2015-12-02 2018-07-17 日本新药株式会社 含有2-{4-[n-(5,6-二苯基吡嗪-2-基)-n-异丙基氨基]丁氧基}-n-(甲磺酰基)乙酰胺的医药组合物
WO2018162527A1 (en) * 2017-03-08 2018-09-13 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising selexipag

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316055B (https=) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
CN104761509A (zh) 2008-02-28 2015-07-08 日本新药株式会社 纤维化抑制剂
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
HRP20151443T1 (hr) 2008-06-23 2016-01-29 Nippon Shinyaku Co., Ltd. Terapijsko sredstvo protiv stenoze kralježniäśnog kanala
CN102065864B (zh) 2008-06-23 2012-11-21 日本新药株式会社 炎性肠病治疗剂
LT2447254T (lt) 2009-06-26 2018-01-10 Nippon Shinyaku Co., Ltd. Kristalai
WO2011024874A1 (ja) 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
HK1198358A1 (en) 2011-08-12 2015-04-10 Ascendis Pharma A/S Sustained release composition of prostacyclin
EP2913047B1 (en) 2012-10-29 2019-05-08 Cardio Incorporated Pulmonary disease-specific therapeutic agent
TW201936175A (zh) * 2018-02-21 2019-09-16 日商日本新藥股份有限公司 粒狀組合物、粒狀組合物之製造方法、及粒狀組合物之溶出性改善方法
JP2022532076A (ja) * 2019-05-06 2022-07-13 アクテリオン ファーマシューティカルズ リミテッド サルコイドーシス関連肺高血圧症の治療方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108289890A (zh) * 2015-12-02 2018-07-17 日本新药株式会社 含有2-{4-[n-(5,6-二苯基吡嗪-2-基)-n-异丙基氨基]丁氧基}-n-(甲磺酰基)乙酰胺的医药组合物
WO2018162527A1 (en) * 2017-03-08 2018-09-13 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising selexipag

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116392491A (zh) * 2023-04-11 2023-07-07 广东省实验动物监测所 司来帕格的药物组合物及其制备方法

Also Published As

Publication number Publication date
EP4048235A1 (en) 2022-08-31
ECSP22040921A (es) 2022-06-30
PH12022550937A1 (en) 2023-06-14
BR112022007207A2 (pt) 2022-07-26
JP2022553313A (ja) 2022-12-22
WO2021078835A1 (en) 2021-04-29
MX2022004882A (es) 2022-08-04
CA3154802A1 (en) 2021-04-29
KR20220087443A (ko) 2022-06-24
PE20221455A1 (es) 2022-09-21
JP2025074286A (ja) 2025-05-13
JP7646646B2 (ja) 2025-03-17
JOP20220093A1 (ar) 2023-01-30
AU2020369912A1 (en) 2022-04-14
US20220401441A1 (en) 2022-12-22
IL292354A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
JP7646646B2 (ja) セレキシパグを含む医薬組成物
TWI583384B (zh) 包含４－胺基－５－氟－３－［６－（４－甲基哌嗪－１－基）－１ｈ－苯并咪唑－２－基］－１ｈ－喹啉－２－酮乳酸鹽單水合物之醫藥組合物
JP6061438B2 (ja) ジアミン誘導体含有医薬組成物
EP0749308B1 (en) Film coated tablet of paracetamol and domperidone
US20160101105A1 (en) High drug load tablet
KR20130093015A (ko) 트라마돌 및 콕시브의 공결정의 약학적 조성물
JP5749247B2 (ja) 経口用徐放性固形製剤
WO2010147169A1 (ja) 溶出性の改善された医薬組成物
CN105338970B (zh) 包含他达拉非和坦洛新的药物胶囊复合制剂
AU2020377451B2 (en) Oral formulation of X842
WO2019098300A1 (ja) 放出制御製剤
CN112449601A (zh) 含纳呋拉啡口腔崩解片
JP2010520891A (ja) ネビラピンの徐放性製剤
JP5318400B2 (ja) レボフロキサシン含有錠剤
JP7634525B2 (ja) 治療用製剤およびその使用
AU2023227540A1 (en) Therapeutic compounds, formulations, and use thereof
JP5295506B2 (ja) レボフロキサシン含有錠剤
WO2016012898A1 (en) Oral pharmaceutical composition of lurasidone
ES2963886T3 (es) Comprimidos que contienen tamsulosina y solifenacina
JP2011527316A (ja) 直接打錠によるアリスキレン錠剤
JP2026509613A (ja) （４ｓ）－２４－クロロ－４－エチル－７３－フルオロ－３５－メトキシ－３２，５－ジオキソ－１４－（トリフルオロメチル）－３２ｈ－６－アザ－３（４，１）－ピリジナ－１（１）－［１，２，３］トリアゾラ－２（１，２），７（１）－ジベンゼナヘプタファン－７４－カルボキサミドを含む医薬剤形
TW202227070A (zh) Fxr促效劑之固態分散體調配物
HK1143095B (en) Zibotentan composition containing mannitol and microcrystalline cellulose
HK1143095A1 (en) Zibotentan composition containing mannitol and microcrystalline cellulose

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination